Importance of genetic factors in the regulation of diazepam metabolism

التفاصيل البيبلوغرافية
العنوان: Importance of genetic factors in the regulation of diazepam metabolism
المؤلفون: Thomas K. Henthorn, Leif Bertilsson, Tomas Villén, Emilio J. Sanz, Juliette Säwe, Gunnel Tybring
المصدر: Journal of Clinical Psychopharmacology. 10:59
بيانات النشر: Ovid Technologies (Wolters Kluwer Health), 1990.
سنة النشر: 1990
مصطلحات موضوعية: Adult, Male, medicine.drug_class, Nordazepam, Debrisoquin, Pharmacology, Biology, Mixed Function Oxygenases, Hydroxylation, Benzodiazepines, chemistry.chemical_compound, Pharmacokinetics, Oral administration, medicine, Humans, Pharmacology (medical), Mephenytoin, Volume of distribution, Benzodiazepine, Diazepam, Hydantoins, Smoking, Significant difference, Metabolism, Isoquinolines, Psychiatry and Mental health, Phenotype, chemistry, Female, medicine.drug
الوصف: Single oral 10 mg doses of diazepam and demethyldiazepam were given on different occasions to 16 healthy subjects. The subjects included four poor hydroxylators of debrisoquin and three poor hydroxylators of mephenytoin. There was a correlation between the total plasma clearance of diazepam and demethyldiazepam (rs = 0.83; p < 0.01). There was no relationship between benzodiazepine disposition and debrisoquin hydroxylation. Poor hydroxylators of mephenytoin had less than half the plasma clearance of both diazepam (p = 0.0008) and demethyldiazepam (p = 0.0001) compared with extensive hydroxylators of mephenytoin. The plasma half-lives were longer in poor hydroxylators than they were in extensive hydroxylators of mephenytoin for both diazepam (88.3 ± SD 17.2 and 40.8 ± 14.0 hours; p = 0.0002) and demethyldiazepam (127.8 ± 23.0 and 59.0 ± 16.8 hours; p = 0.0001). There was no significant difference in volume of distribution of the benzodiazepines between the phenotypes. This study shows that the metabolism of both diazepam (mainly demethylation) and demethyldiazepam (mainly hydroxylation) is related to the mephenytoin, but not to the debrisoquin, hydroxylation phenotype. Clinical Pharmacology and Therapeutics (1989) 45, 348–355; doi:10.1038/clpt.1989.40
تدمد: 0271-0749
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caaacb37ff478f6ffd3139cdb8bdbe70Test
https://doi.org/10.1097/00004714-199002000-00016Test
رقم الانضمام: edsair.doi.dedup.....caaacb37ff478f6ffd3139cdb8bdbe70
قاعدة البيانات: OpenAIRE